Sarig Rachel, Tzahor Eldad
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel.
Carcinogenesis. 2017 Apr 1;38(4):359-366. doi: 10.1093/carcin/bgw103.
Regeneration in mammals is restricted to distinct tissues and occurs mainly by expansion and maturation of resident stem cells. During regeneration, even subtle mutations in the proliferating cells may cause a detrimental effect by eliciting abnormal differentiation or malignant transformation. Indeed, cancer in mammals has been shown to arise through deregulation of stem cells maturation, which often leads to a differentiation block and cell transformation. In contrast, lower organisms such as amphibians retain a remarkable regenerative capacity in various organs, which occurs via de- and re-differentiation of mature cells. Interestingly, regenerating amphibian cells are highly resistant to oncogenic transformation. Therapeutic approaches to improve mammalian regeneration mainly include stem-cell transplantations; but, these have proved unsuccessful in non-regenerating organs such as the heart. A recently developed approach is to induce de-differentiation of mature cardiomyocytes using factors that trigger their re-entry into the cell cycle. This novel approach raises numerous questions regarding the balance between transformation and regeneration induced by de-differentiation of mature mammalian somatic cells. Can this balance be controlled artificially? Do de-differentiated cells acquire the protection mechanisms seen in regenerating cells of lower organisms? Is this model unique to the cardiac tissue, which rarely develops tumors? This review describes regeneration processes in both mammals and lower organisms and, particularly, the ability of regenerating cells to avoid transformation. By comparing the characteristics of mammalian embryonic and somatic cells, we discuss therapeutic strategies of using various cell populations for regeneration. Finally, we describe a novel cardiac regeneration approach and its implications for regenerative medicine.
哺乳动物的再生仅限于特定组织,主要通过驻留干细胞的扩增和成熟来实现。在再生过程中,即使增殖细胞中存在细微的突变,也可能通过引发异常分化或恶性转化而产生有害影响。事实上,哺乳动物的癌症已被证明是由于干细胞成熟失调而引发的,这通常会导致分化阻滞和细胞转化。相比之下,诸如两栖动物等低等生物在各种器官中保留了显著的再生能力,这种再生通过成熟细胞的去分化和再分化来实现。有趣的是,正在再生的两栖动物细胞对致癌转化具有高度抗性。改善哺乳动物再生的治疗方法主要包括干细胞移植;但是,这些方法在诸如心脏等非再生器官中已被证明并不成功。最近开发的一种方法是使用能触发成熟心肌细胞重新进入细胞周期的因子来诱导其去分化。这种新方法引发了许多关于成熟哺乳动物体细胞去分化所诱导的转化与再生之间平衡的问题。这种平衡能否被人为控制?去分化细胞是否获得了在低等生物再生细胞中所见的保护机制?这种模式是否仅适用于很少发生肿瘤的心脏组织?本综述描述了哺乳动物和低等生物的再生过程,特别是再生细胞避免转化的能力。通过比较哺乳动物胚胎细胞和体细胞的特征,我们讨论了使用各种细胞群体进行再生的治疗策略。最后,我们描述了一种新的心脏再生方法及其对再生医学的意义。